Shionogi to increase stake in Apnimed within 6 months of IPO

Market overview

Shionogi's strategic investment in Apnimed's IPO filing demonstrates long-term commitment. Given the drug's potential, Shionogi is likely to bolster its ownership to secure control and commercial rights.

regulatory prediction market

Implied probability (Yes)

60%

Closes

2027-01-10

More regulatory markets

• UK government increases teacher pay offer by 2%+ in 2027 — 45% Yes
• FIFA issues formal disciplinary action against Trump by 2026-12-31 — 70% Yes
• UK government to allocate £200M for river clean-up by 2026 — 70% Yes
• FIFA issues formal reprimand against U.S. Soccer for Trump interference — 75% Yes
• Trump administration implements AI guardrails by Q4 2026 — 70% Yes
• Senate blocks OMB grant rule by December 2026 — 72% Yes
• Biden administration approves ICE detention project within 6 months — 40% Yes
• Forge Global secures Anthropic approval within 6 months — 75% Yes

Browse all regulatory markets →